Imaging hypoxia in tumors

Seminars in Nuclear Medicine

Volumn 31, Issue 4, 2001, Pages 321-329

  Ballinger, James R ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 NITROIMIDAZOLE; 2 NITROIMIDAZOLE DERIVATIVE; AZOMYCIN ARABINOSIDE I 123; BRU 5921; COPPER 64; COPPER 67; CYCLAM; ETANIDAZOLE; ETANIDAZOLE F 18; FLAVOXATE; IODINE 123; MISONIDAZOLE; OXO[3,3,9,9 TETRAMETHYL 1 (2 NITRO 1H IMIDAZOL 1 YL) 4,8 DIAZAUNDECANE 2,10 DIONEDIOXIMATO]TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT; SENAZOLE; TECHNETIUM 99M; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; UPENAZIME;

ARTICLE; CANCER RADIOTHERAPY; DIAGNOSTIC IMAGING; DISEASE COURSE; DRUG HALF LIFE; DRUG STRUCTURE; HUMAN; HYPOXIA; INTERMETHOD COMPARISON; ISOTOPE LABELING; NONHUMAN; OXYGEN TENSION; POSITRON EMISSION TOMOGRAPHY;

EID: 0034753330     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2001.26191     Document Type: Article

References (98)

1. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy
2. Definitive evidence for hypoxic cells influencing cure in cancer therapy
3. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors
4. Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV
5. Improved response of colon cancer xenografts to radioimmunotherapy with pentoxifylline treatment
6. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
7. Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumors
8. Genetic instability induced by the tumor microenvironment
9. Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies
10. 2 predicts survival in advanced cancer of the uterine Cervix
11. Heterogeneity of polarographic oxygen tension measurements in cervix cancer: An evaluation of within and between tumor variability, probe position, and track depth
12. Optical sensor-based oxygen tension measurements correspond with hypoxia marker binding in three human tumor xenograft lines
13. Oxygenation predicts radiation response and survival in patients with cervical cancer
14. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
15. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
16. Tumor oxygenation predicts for likelihood of distant metastases in human soft tissue sarcoma
17. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age
18. Cervix cancer oxygenation measured following external radiation therapy
19. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis
20. Hypoxic sensitizers - Implications for radiation therapy
21. Use of 2-nitroimidaxoles as bioreductive markers for tumor hypoxia
22. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]
23. Hypoxia marker labeling in tumor biopsies: Quantification of labeling variation and criteria for biopsy sectioning
24. Pimonidazole: A novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma
25. Hypoxia and vascular endothelial growth factor expression in human squamous Cell carcinomas using pimonidazole as a hypoxia marker
26. Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas
27. Detection of hypoxia in human squamous cell carcinoma by EF 5 binding
28. Detection of hypoxic cells in a murine tumor with the use of the comet assay
29. The comet assay in clinical practice
30. Synthesis and characterization of congeners of misonidazole for imaging hypoxia
31. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells
32. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro
33. 18F]fluoromisonidazole
34. 18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia
35. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia
36. 18F]-EF 1
37. 18F]-EF 1
38. 18F]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure
39. Single-photon emission computed tomography and positron-emission tomography assays for tissue oxygenation
40. Radioiodinated 1-(5-iodo-5-deoxy-beta-D-arabinofuranosyl) -2- nitroimidazole (iodoazomycin arabinoside: IAZA): A novel marker of tissue hypoxia
41. 123/125I] iodo-5-deoxyarabinofuranosyl)-2-nitroimidazole, a hypoxic cell marker
42. Synthesis, radiolabeling, and biodistribution of putative metabolites of iodoazomycin arabinoside
43. An improved synthesis of α-AZA, α-AZP and α-AZG, the precursors to clinical markers of tissue hypoxia
44. The synthesis and radiolabeling of novel markers of tissue hypoxia of the iodinated azomycin nucleoside class
45. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays
46. 99mTc]HL-91: Correlation with microelectrode measurements
47. 131I]-iodoerythronitroimidazole
48. TcO(PnAO-1-[2-nitroimidazole]) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: Synthesis, characterization, and xanthine oxidase-catalyzed reduction
49. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS 181321) as a marker of tumor hypoxia
50. Modifying the in vitro accumulation of BMS181321, a technetium-99m-nitroimidazole, with unlabelled nitroaromatics
51. Preliminary experience with technetium-99m BMS-181321, a nitroimidazole, in the detection of cerebral ischemia associated with acute stroke
52. BRU59-21, a second-generation technetium-99m-labeled 2-nitroimidazole for imaging hypoxia in tumors
53. Role of NADPH cytochrome P450 reductase in the hypoxic accumulation and metabolism of BRU59-21, a technetium-99m-nitroimidazole for imaging tumor hypoxia
54. Synthesis and evaluation of two technetium-99m-labeled peptidic 2-nitroimidazoles for imaging hypoxia
55. Targeting hypoxia in tumors using 2-nitroimidazoles with peptidic chelators for technetium-99m: Effect of lipophilicity
56. A novel amine-dioxime chelator for technetium-99m: Synthesis and evaluation of 2-nitroimidazole-containing analogues as markers for hypoxic cells
57. 99mTc labeled metronidazole
58. Technetium-99m-cyclam AK 2123: A novel marker for tumor hypoxia
59. Evaluation of Cu-PTSM as a tracer of tumor perfusion: Comparison with labeled microspheres in spontaneous canine neoplasms
60. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential
61. Redox-active metal complexes for imaging hypoxic tissues: Structure-activity relationships in copper(II) bis(thiosemicarbazone) complexes
62. Design of hypoxia-targeting radiopharmaceuticals: Selective uptake of copper- 64 complexes in hypoxic cells in vitro
63. Towards new transition metal-based hypoxic selective agents for therapy and imaging
64. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model
65. Technetium-labeled agents for imaging tissue hypoxia in vivo
66. The chemical characterisation of the tumor imaging agent 99mTc-HL91
67. 99mTc-BnAO (HL-91): A non-nitroaromatic compound for hypoxic cell detection
68. 99mTc-HL91, a putative hypoxic tracer, to detection of tumor hypoxia
69. 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo
70. Technetium-99m HL91 uptake as a tumor hypoxia marker: Relationship to tumor blood flow
71. 99mTc-labeled HL-91; Prognox): Noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid
72. 99mTc-analog of Cu-DTS as an agent for imaging hypoxia
73. 18F]-fluoromisonidazole
74. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography
75. Hypoxia in human glioblastoma: Demonstration by PET with fluorine-18-fluoromisonidazole
76. Fluorine- 18 fluoromisonidazole tumor to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma
77. 18F]fluoromisonidazole: A pretherapy study of 37 patients
78. 123I-IAZA in healthy volunteers
79. 123I-iodoazomycin arabinoside: Preliminary report of a clinical Study
80. Imaging tumor hypoxia and tumor perfusion
81. Measurement of hypoxia in human tumours by non-invasive SPECT imaging of iodoazomycin arabinoside
82. Technetium-99m-labeled HL91 to identify tumor hypoxia: Correlation with fluorine-18-FDG
83. 99mTc-labelled HL91, a novel marker of tissue hypoxia: A pilot study
84. 4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer
85. Evaluation of tumor hypoxia with Cu-60 ATSM and PET
86. A comparison in individual murine tumors of techniques for measuring oxygen levels
87. The potential for myocardial imaging with hypoxia markers
88. Association between tissue hypoxia and elevated non-protein sulphydryl concentrations in human cervical carcinoma xenografts
89. Protection from radiation-induced DNA single-strand breaks by induction of nuclear metallothionein
90. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia
91. Effect of nitroimidazole sensitizers on in vitro glycolytic metabolism of hypoxic squamous cell carcinoma
92. Magnetic resonance imaging techniques for monitoring changes in tumor oxygenation and blood flow
93. An evaluation of near infrared spectroscopy and cryospectrophotometry estimates of haemoglobin oxygen saturation in a rodent mammary tumor model
94. Preclinical development and current status of the fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitro-1-imidazolyl)acetamide (SR 4554/CRC 94/17): A non-invasive diagnostic probe for the measurement of tumor hypoxia by magnetic resonance spectroscopy and imaging, and by positron emission tomography. Anti
95. Selective boosting of tumor subvolumes
96. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors
97. Gene delivery to hypoxic cells in vitro
98. Clinical outcome and tumor microenvironmental effects of accelerated radiotherapy with carbogen and nicotinamide